Cut through the noise.
Trade on the signal.
A weekly synthesis of institutional-grade financial reports and market mechanics.
No spam. Unsubscribe anytime.
Veru Inc
2 of 2 reportsVERU$2.95
-1.34%sabizabulinVERU
Part 2: New Red Flags Emerge From Veru’s Phase 3 Covid Trial, Suggesting An FDA Rejection Is Likely
White Diamond Research exposes critical flaws in Veru's COVID-19 drug trial, revealing data integrity issues, methodological problems, and potential FDA rejection risks for sabizabulin treatment
VERU$2.95
-1.34%VERUVERU
Part 1: New Red Flags Emerge From Veru’s Phase 3 Covid Trial, Suggesting An FDA Rejection Is Likely
Veru's Sabizabulin COVID-19 drug faces potential FDA rejection due to critical Phase 3 trial design flaws, small sample size, patient selection issues, and questionable mortality data suggesting ineffective treatment